Travera’s new technology can predict how patients will respond to hundreds of different drugs or drug combinations before the patients even take the drugs. Their new measurement tool, the Suspended Microchannel Resonator […]
The Cancer Progress Report
The Cancer Progress Report delivers crisp headlines of progress at emerging companies developing, in many cases, breakthroughs. It is a fast and efficient must read for anyone serious in the field. For […]
Cancer Innovations Database to premiere at October Cancer Conference
The Cancer Investor Conference October 30th & 31st to Unveil Global Cancer Database for Investors NEW YORK – Altru Institute, organizer of the Global Cancer Consortium, has announced that a global […]
Bioinformatics Special Report, Part I: Where Does Biotechnology Data Come From?
Bioinformatics is the field of science involved with using computational methods to convert raw biological data into meaningful biological paradigms. Part I of this article will discuss how bioinformatics data is generated. It will focus on the methods used to collect this data, and the companies that support this collection.
Release: Actium Biosystems Appoints Distinguished Pharmaceutical Scientist Dr. Jessie L.-S. Au to its Scientific Advisory Board
Actium Cancer Treatment (ACT) platform’s controlled heat (hyperthermia) has the potential to substantially increase the efficacy of chemotherapy and radiation First application: non-muscle-invasive bladder cancer (NMIBC).
Atossa Genetics’ Portfolio Can Detect Breast Cancer. But Can These Products Eradicate It?
Atossa Genetics believes it can prevent breast cancer by 2020 — and in the meantime, capture a unique market opportunity — with their novel cellular and molecular diagnostic risk assessment products for early detection. Yet in a burgeoning diagnostics space, and rapid advancement in cancer therapeutics, will this company find a niche?
DelMar IPO Obscurity Could Offer Investors Favorable Entry
DelMar Pharmaceuticals (DMPI.OB) started 2013 with a revealing corporate update on January 8th. In the update, president and CEO Jeffrey Bacha outlined his goals with an exciting year ahead for the company and its employees. Mr. Bacha focused primarily on the company’s lead product candidate, VAL-083, a small molecule (chemotherapy) agent that DelMar is developing in a dose escalation trial for recurrent glioblastoma multiforme (GBM).
Release: Idrasil, Cannabis in a Pill Founder to Exhibit at the Rx for Wealth Symposium April 27 in Huntington Beach
Huntington Beach, April 23, 2013 – Steele C. Smith, III and Medical Director Mark S. Wagner M.D. to exhibit at the Rx for Wealth Network Symposium this Weekend April 27th at the Huntington Beach Hilton.